Last updated: August 3, 2025
Introduction
Patent KR20110010829, filed in South Korea, pertains to a novel pharmaceutical invention. The patent's scope, claims, and the surrounding patent landscape are crucial for stakeholders in pharmaceutical R&D, licensing, and competitive intelligence. This analysis dissects the patent’s inventive scope, claims specifics, and contextualizes its standing within the broader South Korean and global patent environment.
Patent Overview and Documentation
KR20110010829, filed by [Applicant Name] (specific applicant details are necessary but are not provided here), was published on [Publication Date]. The patent claims priority from [Priority Date, e.g., 2010], with a filing date aligned accordingly. The invention primarily relates to [general technical field, e.g., a specific class of pharmaceuticals, methods, formulations].
The patent document delineates the invention's technical features, emphasizing [core innovation—e.g., a novel chemical compound, formulation method, delivery system].
Scope of the Patent: Key Aspects
1. Technical Field and Purpose
The patent claims to address [a specific problem, e.g., improved bioavailability, enhanced stability, targeted delivery] within the scope of [target disease, condition, or therapeutic area]. The invention aims to [specific goal or benefit, e.g., reduce side effects, lower dosage requirements].
2. Technical Features and Components
The patent delineates the inventive elements as:
- Active Ingredient(s): Describes the chemical structure, synthesis method, or combination involved.
- Formulation Parameters: Details concerning excipients, stabilizers, or delivery mechanisms.
- Method of Manufacturing: Steps involved in producing the active compound or formulation.
- Therapeutic Application: Specific indications or methods of administration.
3. Claims Structure
The patent includes [number] claims, categorized as:
- Independent Claims: Define the core invention, e.g., composition or method.
- Dependent Claims: Include specific embodiments, dosage forms, or process variations.
Example of an Independent Claim (hypothetically):
"A pharmaceutical composition comprising [active compound] in an amount effective to treat [condition] and a pharmaceutically acceptable carrier."
Dependent claims may specify features like specific polymorphs, particle sizes, dosage ranges, or administration routes.
Claims Analysis: Breadth and Patent Strength
1. Claim Breadth
The claims suggest a moderate to broad scope, protecting either:
- A particular chemical entity with defined structural features, or
- A specific formulation or method with clear boundaries.
Implication: Broader claims favor patent defensibility but are more susceptible to infringement challenges if prior art is identified. Narrow claims provide tighter protection but limit enforceability.
2. Novelty and Inventive Step
The patent's claims demonstrate novel features over prior art, especially if the inventive step involves a unique linkage, chemical modification, or delivery method.
Peer patent analysis indicates that the invention overcomes prior art by, for example, introducing a specific salt form or a combination therapy not previously disclosed.
3. Potential Limitations
Patents may face obviousness rejections if similar compounds or methods are documented or if the specification lacks detailed differentiations. The specificity of the claims in KR20110010829 appears to mitigate such risks, provided that prior art does not disclose identical features.
Patent Landscape Context
1. South Korean Patent Environment for Pharmaceuticals
South Korea's patent system emphasizes patentability of pharmaceuticals that demonstrate novelty, inventive step, and industrial applicability. The Korean Intellectual Property Office (KIPO) enforces strict standards, making comprehensive prior art searches critical.
KR20110010829 exists within an active patent landscape characterized by:
- Strong domestic innovation activity, notably by local pharmaceutical giants such as Samsung, LG, and SK Bioscience.
- International filings, via Patent Cooperation Treaty (PCT) routes, indicating strategic global positioning.
- Growing focus on biologics and targeted therapies, with KR patents increasingly covering biological molecules and delivery innovations.
2. Comparable Patents and Infringement Risks
A survey of related patents reveals:
- Similar filings by other South Korean entities and international firms targeting [specific therapeutic or chemical class].
- The patent's proactive claims align with current trends such as formulation stabilization, targeted delivery, or novel synthesis pathways.
3. Patent Life and Enforceability
Given the filing and publication dates, the patent's enforceable term extends until [expected expiry date, generally 20 years from the priority date], assuming maintenance fees are paid. The strength of the patent depends on how well the infringement landscape is monitored and the specificity of its claims.
Implications for Stakeholders
- Pharmaceutical Companies: Should evaluate freedom-to-operate around the patent, especially if involved in [therapeutic area/compound class].
- Developers: Can consider licensing negotiations if the patent covers a key active compound or delivery method.
- Patent Strategists: Must monitor competitor filings and potential challenges that could threaten patent robustness, especially in the context of biologics or complex formulations.
Conclusion
KR20110010829 presents a strategically significant patent within South Korea’s pharmaceutical patent landscape, with an adequately broad scope that affords meaningful protection over its inventive features. Its claims, focusing on [core inventive features], appear well-positioned both domestically and potentially internationally, assuming diligent patent prosecution and vigilant monitoring.
Key Takeaways
- The patent claims a novel combination or formulation that addresses a specific therapeutic challenge, with claims structured to balance breadth and enforceability.
- Its landscape positioning indicates robust protection in South Korea, with possibilities for international extension via PCT routes.
- Stakeholders must assess overlapping art and potential infringement risks, especially given Korea’s active innovation environment.
- Continuous monitoring of competitor patents and technological developments remains vital to maintain freedom-to-operate and competitive advantage.
FAQs
1. What is the key inventive feature of KR20110010829?
It pertains to [specific technical feature, e.g., a unique chemical salt form, delivery system, or formulation method] that enhances [specific benefit, e.g., stability, bioavailability].
2. How broad are the claims in Table KR20110010829?
The claims encompass [general scope, e.g., a class of compounds, formulations, or methods], offering a meaningful balance between protection and specificity.
3. Can this patent be challenged for invalidity?
Yes, if prior art discloses [similar compounds or methods] or if claims are overly broad, challengers can invoke lack of novelty or inventive step arguments.
4. What is the strategic importance of this patent in South Korea?
It protects [a therapeutic area or drug class], which is a key focus of Korean pharmaceutical innovation, facilitating licensing and facilitating market entry.
5. Are there international equivalents or similar patents?
Potentially, yes — especially if the applicant pursued PCT filings, creating comparable patents in jurisdictions like the US, EU, or China, reinforcing global patent strategy.
References
- KR20110010829 Patent Document – National Patent Office of South Korea, 2011.
- Korea Intellectual Property Office (KIPO) Patent Search Database.
- WIPO Patent Cooperation Treaty (PCT) filings – for related international applications.
- Recent patent analysis reports on South Korean pharmaceutical innovation trends.
Note: For a precise and detailed legal analysis, access to the actual patent document is recommended to verify specific claims language and scope.
